The potential of three whole blood microRNAs to predict outcome and monitor treatment response in sarcoid-bearing equids.

Hamza, E; Cosandey, J; Gerber, V; Koch, C; Unger, L (2023). The potential of three whole blood microRNAs to predict outcome and monitor treatment response in sarcoid-bearing equids. Veterinary research communications, 47(1), pp. 87-98. Springer 10.1007/s11259-022-09930-7

[img]
Preview
Text
Hamza2022_Article_ThePotentialOfThreeWholeBloodM.pdf - Published Version
Available under License Creative Commons: Attribution (CC-BY).

Download (1MB) | Preview

MicroRNAs (miRNAs) have been proposed as biomarkers for equine sarcoid (ES) disease. In this study, the suitability of three whole blood miRNAs to diagnose ES and to predict and monitor the outcome of therapy was explored. Using reverse transcription-quantitative polymerase chain reaction (RT-qPCR), expression levels of eca-miR-127, eca-miR-379, and eca-miR-432 in whole blood of ES-affected equids before and at least one year after therapy were compared to those of unaffected control equids. Associations of age, sex, species, diagnosis, and therapy outcome with miRNA expression levels were examined using general linear models. In total, 48 ES-affected equids and 47 control equids were recruited. From the affected animals, 31 responded favorably to treatment, and 17 demonstrated a failure of therapy. None of the tested miRNAs were influenced by age. Male equids showed increased expression of eca-miR-127 compared to females and horses showed higher expression levels of eca-miR-379 and eca-miR-432 than donkeys. Eca-miR-127 was confirmed as a diagnostic discriminator between ES-affected and control equids. No difference in miRNA profiles before therapy was found when comparing ES-affected equids with success vs. failure of therapy. Eca-miR-379 and eca-miR-432 decreased over time in horses where therapy was successful, but not in those cases where it failed. Biological variables influence equine whole blood miRNA expression, which may complicate biomarker validation. While none of the tested miRNAs could predict the response to therapy in ES-affected equids and eca-miR-127 showed poor diagnostic accuracy for ES, eca-miR-379 and eca-miR-432 miRNAs might allow refinement of monitoring of success of ES therapy.

Item Type:

Journal Article (Original Article)

Division/Institute:

05 Veterinary Medicine > Department of Clinical Veterinary Medicine (DKV) > ISME Equine Clinic Bern > ISME Equine Clinic, Internal medicine
05 Veterinary Medicine > Department of Clinical Veterinary Medicine (DKV)

UniBE Contributor:

Hamza, Eman, Cosandey, Jeanne, Gerber, Vinzenz, Koch, Christoph, Unger, Lucia

Subjects:

600 Technology > 630 Agriculture

ISSN:

1573-7446

Publisher:

Springer

Language:

English

Submitter:

Pubmed Import

Date Deposited:

02 May 2022 08:49

Last Modified:

25 Jan 2023 00:11

Publisher DOI:

10.1007/s11259-022-09930-7

PubMed ID:

35484337

Uncontrolled Keywords:

Biomarker Equine oncology Non-coding RNA Precision medicine

BORIS DOI:

10.48350/169643

URI:

https://boris.unibe.ch/id/eprint/169643

Actions (login required)

Edit item Edit item
Provide Feedback